Page 124 - Read Online

Page 10 of 11 Scirpa et al. Vessel Plus 2022;6:52 https://dx.doi.org/10.20517/2574-1209.2021.74

16. Planté-Bordeneuve V, Suhr OB, Maurer MS, White B, Grogan DR, Coelho T. The Transthyretin amyloidosis outcomes survey
(THAOS) registry: design and methodology. Curr Med Res Opin 2013;29:77-84. DOI PubMed
17. Maurer MS, Hanna M, Grogan M, et al; THAOS Investigators. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS
(Transthyretin amyloid outcome survey). J Am Coll Cardiol 2016;68:161-72. DOI PubMed PMC
18. Conceição I, De Carvalho M. Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late- and
early-onset cases in Portugal. Muscle Nerve 2007;35:116-8. DOI PubMed
19. Gagliardi C, Perfetto F, Lorenzini M, et al. Phenotypic profile of Ile68Leu transthyretin amyloidosis: an underdiagnosed cause of heart
failure. Eur J Heart Fail 2018;20:1417-25. DOI PubMed
20. Quarta C, Longhi S, Cappelli F, et al. Late onset cardiomyopathy due to transthyretin Ile68Leu mutation: a cardiogenic variant of
familial amyloidosis potentially mimicking sarcomeric hypertrophic cardiomyopathy. European Heart Journal 2013;34:P2958-P2958.
DOI
21. Waddington-Cruz M, Wixner J, Amass L, Kiszko J, Chapman D, Ando Y; THAOS investigators. Characteristics of patients with late-
vs early-onset val30met transthyretin amyloidosis from the transthyretin amyloidosis outcomes survey (THAOS). Neurol Ther
2021;10:753-66. DOI PubMed PMC
22. Gentile L, Tournev I, Amass L, Chapman D, Mazzeo A; THAOS investigators. phenotypic differences of glu89gln genotype in ATTR
amyloidosis from endemic loci: update from THAOS. Cardiol Ther 2021;10:481-90. DOI PubMed PMC
23. Parman Y, Adams D, Obici L, et al; European Network for TTR-FAP (ATTReuNET). Sixty years of transthyretin familial amyloid
polyneuropathy (TTR-FAP) in Europe: where are we now? Curr Opin Neurol 2016;29 Suppl 1:S3-S13. DOI PubMed PMC
24. Rapezzi C, Perugini E, Salvi F, et al. Phenotypic and genotypic heterogeneity in transthyretin-related cardiac amyloidosis: towards
tailoring of therapeutic strategies? Amyloid 2006;13:143-53. DOI PubMed
25. Yamamoto S, Wilczek HE, Nowak G, et al. Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center
experience over 16 years. Am J Transplant 2007;7:2597-604. DOI PubMed
26. Quarta CC, Buxbaum JN, Shah AM, et al. The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med
2015;372:21-9. DOI PubMed PMC
27. Sattianayagam PT, Hahn AF, Whelan CJ, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated
with transthyretin alanine 60 variant. Eur Heart J 2012;33:1120-7. DOI PubMed
28. Mazzeo A, Russo M, Di Bella G, et al. Transthyretin-related familial amyloid polyneuropathy (ttr-fap): a single-center experience in
sicily, an italian endemic area. J Neuromuscul Dis 2015;2:S39-48. DOI PubMed PMC
29. Mariani LL, Lozeron P, Théaudin M, et al; French Familial Amyloid Polyneuropathies Network (CORNAMYL) Study Group.
Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France. Ann Neurol 2015;78:901-16.
DOI PubMed PMC
30. Ihse E, Ybo A, Suhr O, Lindqvist P, Backman C, Westermark P. Amyloid fibril composition is related to the phenotype of hereditary
transthyretin V30M amyloidosis. J Pathol 2008;216:253-61. DOI PubMed
31. Gustafsson S, Ihse E, Henein MY, Westermark P, Lindqvist P, Suhr OB. Amyloid fibril composition as a predictor of development of
cardiomyopathy after liver transplantation for hereditary transthyretin amyloidosis. Transplantation 2012;93:1017-23. DOI PubMed
32. Pilebro B, Suhr OB, Näslund U, Westermark P, Lindqvist P, Sundström T. (99m)Tc-DPD uptake reflects amyloid fibril composition in
hereditary transthyretin amyloidosis. Ups J Med Sci 2016;121:17-24. DOI PubMed PMC
33. Caponetti AG, Rapezzi C, Gagliardi C, et al; THAOS Investigators. Sex-related risk of cardiac involvement in hereditary transthyretin
amyloidosis: insights from THAOS. JACC Heart Fail 2021;9:736-46. DOI PubMed
34. Batra J, Rosenblum H, Defilippis EM, et al. Sex differences in the phenotype of transthyretin cardiac amyloidosis due to Val122Ile
mutation: insights from noninvasive pressure-volume analysis. J Card Fail 2021;27:67-74. DOI PubMed PMC
35. Rapezzi C, Riva L, Quarta CC, et al. Gender-related risk of myocardial involvement in systemic amyloidosis. Amyloid 2008;15:40-8.
DOI PubMed
36. Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti-Pellié C, Planté-Bordeneuve V. Heterogeneity of penetrance in familial
amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid 2008;15:181-6. DOI PubMed PMC
37. Iorio A, De Lillo A, De Angelis F, et al. Non-coding variants contribute to the clinical heterogeneity of TTR amyloidosis. Eur J Hum
Genet 2017;25:1055-60. DOI PubMed PMC
38. Alves-Ferreira M, Azevedo A, Coelho T, et al. Beyond Val30Met transthyretin (TTR): variants associated with age-at-onset in
hereditary ATTRv amyloidosis. Amyloid 2021;28:100-6. DOI PubMed
39. Polimanti R, Di Girolamo M, Manfellotto D, Fuciarelli M. Functional variation of the transthyretin gene among human populations
and its correlation with amyloidosis phenotypes. Amyloid 2013;20:256-62. DOI PubMed
40. Musunuru K, Hershberger RE, Day SM, et al; American Heart Association Council on Genomic and Precision Medicine; Council on
Arteriosclerosis; Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; and Council on Clinical
Cardiology. Genetic testing for inherited cardiovascular diseases: a scientific statement from the American heart association. Circ
Genom Precis Med 2020;13:e000067. DOI PubMed
41. Witteles RM, Bokhari S, Damy T, et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC Heart Fail
2019;7:709-16. DOI PubMed
42. Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-
propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46:1076-84. DOI PubMed